Wayrilz (rilzabrutinib), immune thrombocytopenia access
Persistent or chronic immune thrombocytopenia (ITP) in adults with insufficient response to a previous treatment ยท Hematology (immune thrombocytopenia)
Ask about Wayrilz
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Wayrilz
Wayrilz (rilzabrutinib) is an oral reversible covalent Bruton's tyrosine kinase (BTK) inhibitor from Sanofi, originally developed by Principia Biopharma. It is indicated for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. It earned US FDA approval in 2025.
Rilzabrutinib's reversible binding profile distinguishes it from earlier irreversible BTK inhibitors and supports a dual mechanism in ITP, modulating both autoantibody-driven platelet destruction (via B-cell and Fc-receptor signalling) and inflammatory macrophage activity, without targeting platelets directly.
Where Wayrilz is not yet registered in a patient's home country, Reserve Meds coordinates supply from US specialty wholesalers via Named Patient Program (NPP) and personal-import pathways, against a destination-country prescription and the regulatory paperwork specific to each jurisdiction.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Wayrilz
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Wayrilz for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Wayrilz is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list rilzabrutinib as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Wayrilz in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Wayrilz
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Wayrilz if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Wayrilz for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Wayrilz through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Wayrilz. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Wayrilz through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Wayrilz to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Wayrilz to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Wayrilz cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Wayrilz?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.